Please login to the form below

Not currently logged in

UCB integrates two CROs into its clinical trial teams

Belgium pharma company agrees global research outsourcing deal with Parexel and PRA

UCB has signed partnership deals with two contract research organisations (CROs) that will see them operate as part of its global drug development team.

The agreements with Parexel and PRA will cover all the Brussels-based pharma company's new clinical trial programmes and they are also aimed at making UCB's studies more efficient and cost effective.

UCB's chief medical officer Iris Loew-Friedrich said: "We are pleased to announce these strategic partnerships as UCB aims to expand its global drug development activities, including in Asia.

“These partnerships represent long-term, win-win commitments to an outsourcing model focused on maximising the effectiveness of each participant's resources in clinical operations.”

The new arrangements will essentially see Parexel and PRA become integrated members of UCB's study teams, Loew-Friedrich added.

The company was light on the detail of the new agreements, saying the two CROs would “drive UCB's operational clinical development activities” and provide focused global operational clinical development activities.

Parexel said its service offering to UCB would include consulting expertise in regulatory affairs and commercialisation, while PRA said it has services for clinical studies across all phases and therapeutic areas with particular experience in CNS indications.

17th November 2011


Featured jobs

Subscribe to our email news alerts


Add my company
Rainmaker Healthcare Communications

Rainmaker is an independent, award-winning communications agency with offices in London and Atlanta. Our experience across pharmaceuticals, generics, OTC, medical...

Latest intelligence

If you’re not thinking segmentation, you’re not thinking
Having a background in market research I’ve been lucky to work on a number of customer segmentations in my time but working in creative communications it is still too rare...
Improving Outcomes in the Treatment of Opioid Dependence Highlights Report
The 16th annual ‘Improving Outcomes in the Treatment of Opioid Dependence’ (IOTOD)conference took place at the Hilton Madrid Airport hotel on 15–16 May 2018....
Londonvelophobia (fear of cycling in London) – debunked